Lilly Reports Strong First-Quarter 20...((10.5) 23.8 ...),Health

Date:4/20/2009

(10.5) 23.8 --------- ---------- Other income (expense) (70.7) 20.3 Income before income taxes 1,683.4 1,056.3 59% Income taxes 370.3 (8.0) NM --------- ---------- Net income $1,313.1 $1,064.3 23% ========= ========== Earnings per share - basic $1.20 $0.97 24% ========= ========== Earnings per share - diluted $1.20 $0.97 24% ========= ========== Dividends paid per share $0.49 $0.47 4% Weighted-average shares outstanding (thousands) - basic 1,097,224 1,093,866 Weighted-average shares outstanding (thousands) - diluted 1,097,256 1,094,056 NM - not meaningful

      Eli Lilly and Company
      Operating Results  (Unaudited) - Pro forma Non-GAAP
      (Dollars in millions, except per share data)

                                         Three Months Ended
                                             March 31
                                         2009       2008(a)(b)      % Chg.
                                     --------------------------------------
      Net product sales               $4,891.8        $4,734.8         3%
      Collaboration and
       other revenue                     155.2           175.7      (12)%
                                     ----------      ----------
      Total Revenue                    5
'/>"/>
SOURCE  Eli Lilly and Company
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 
Related medicine news :

1. Statement of Eli Lilly and Company on Dr. David Egilman Settlement:
2. Robert J. Heine, M.D., Ph.D., F.R.C.P. to Join Lilly; Distinguished Diabetes Expert to Lead Diabetes/Endocrine Medical Division
3. Lauren Marangell, M.D. to Join Lilly; Internationally Recognized Expert in Depression Joins as Distinguished Lilly Scholar
4. Genentech/Roches Lucentis and Eli Lillys Ruboxistaurin Will Drive the Diabetic Retinopathy and Nephropathy Drug Markets
5. Lillys CEO Calls for Reform of Nations Drug Safety System
6. Lilly Announces Updates to the Zyprexa and Symbyax U.S. Labels
7. Lilly Grant to VA Will Enhance Services for Returning Combat Veterans
8. Lilly Delivers Strong Third-Quarter Results
9. Lilly and MacroGenics Announce Licensing and Collaboration Agreement
10. Eli Lilly and Company Aids California Recovery Effort
11. Eli Lilly and Company Announces 2007 Lilly Reintegration Awards Recipients